NEW YORK (GenomeWeb News) – Decode Genetics reported after the close of the market on Wednesday that its second-quarter revenues nearly doubled to $15 million from $7.6 million year over year.
The Reykjavik, Iceland-based biopharmaceutical and molecular diagnostics firm noted in a statement that it also has $15.1 million in deferred revenue that will be recognized over future reporting periods.
Decode’s net loss increased 13.6 percent to $18.4 million, or $.30 per share, from $16.2 million, or $.27 per share. The quarter includes $1.2 million in non-operating expense tied to a revaluation of the firm’s non-current auction rate security investments. Decode also had taken charges in each of the previous two quarters related to the auction-rate securities.
The company’s R&D spending was cut 44.8 percent to $8 million from $14.5 million year over year, while its SG&A expenses edged up 4.4 percent to $7.1 million from $6.8 million.
Decode finished the quarter with $23.7 million in cash, cash equivalents, and current investments.
“As we ramp up our sales efforts in diagnostics and deCODEme, our discovery engine is providing us with a steady stream of intellectual property and content for new tests that leverage the same product development infrastructure,” Kari Stefansson, CEO of Decode, said in a statement.